Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1972 Aug;35(4):514–519. doi: 10.1136/jnnp.35.4.514

Amine metabolites in the cerebrospinal fluid in Huntington's chorea

G Curzon 1,2, John Gumpert 1,2, David Sharpe 1,2
PMCID: PMC494114  PMID: 4261957

Abstract

The amine metabolites HVA and 5-HIAA in the lumbar CSF of 15 patients with Huntington's chorea were determined. A negative correlation was found between the severity of symptoms and the CSF HVA, but not 5-HIAA levels. The mean HVA concentration was lower than that of a group of patients with miscellaneous neurological disorders, similar to that of a group with miscellaneous psychiatric disorders and higher than that of a group with Parkinson's disease. The mean 5-HIAA concentration was similar to that of the neurological group and higher than those of the groups with psychiatric disorders or Parkinson's disease. CSF HVA and 5-HIAA concentrations of a single patient with severe akinetic rigid Huntington's chorea were similar to those found in Parkinson's disease. The findings are discussed in relation to previous neuropathological observations and to reported effects of drugs on the choreic symptoms.

Full text

PDF
514

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANDEN N. E., CARLSSON A., DAHLSTROEM A., FUXE K., HILLARP N. A., LARSSON K. DEMONSTRATION AND MAPPING OUT OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS. Life Sci. 1964 Jun;3:523–530. doi: 10.1016/0024-3205(64)90161-4. [DOI] [PubMed] [Google Scholar]
  2. Aquilonius S. M., Sjöström R. Cholinergic and dopaminergic mechanisms in Huntington's chorea. Life Sci I. 1971 Apr 1;10(7):405–414. doi: 10.1016/0024-3205(71)90146-9. [DOI] [PubMed] [Google Scholar]
  3. Ashcroft G. W., Dow R. C., Moir A. T. The active transport of 5-hydroxyindol-3-ylacetic acid and 3-methoxy-4-hydroxyphenylacetic acid from a recirculatory perfusion system of the cerebral ventricles of the unanaesthetized dog. J Physiol. 1968 Dec;199(2):397–425. doi: 10.1113/jphysiol.1968.sp008660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barbeau A. L-dopa and juvenile Huntington's disease. Lancet. 1969 Nov 15;2(7629):1066–1066. doi: 10.1016/s0140-6736(69)90662-x. [DOI] [PubMed] [Google Scholar]
  5. Bernheimer H., Birkmayer W., Hornykiewicz O. Homovanillinsäure im Liquor cerebrospinalis: Untersuchungen beim Parkinson-Syndrom und anderen Erkrankungen des ZNS. Wien Klin Wochenschr. 1966 Jun 10;78(23):417–419. [PubMed] [Google Scholar]
  6. COHEN N. H. The treatment of Huntington's chorea with trifluoperazine (Stelazine). J Nerv Ment Dis. 1962 Jan;134:62–71. [PubMed] [Google Scholar]
  7. Calne D. B., Stern G. M., Laurence D. R., Sharkey J., Armitage P. L-dopa in postencephalitic parkinsonism. Lancet. 1969 Apr 12;1(7598):744–746. doi: 10.1016/s0140-6736(69)91751-6. [DOI] [PubMed] [Google Scholar]
  8. Chase T. N., Schnur J. A., Gordon E. K. Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders. Neuropharmacology. 1970 May;9(3):265–268. doi: 10.1016/0028-3908(70)90075-4. [DOI] [PubMed] [Google Scholar]
  9. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  10. Curzon G., Gumpert E. J., Sharpe D. M. Amine metabolites in the lumbar cerebrospinal fluid of humans with restricted flow of cerebrospinal fluid. Nat New Biol. 1971 Jun 9;231(23):189–191. doi: 10.1038/newbio231189a0. [DOI] [PubMed] [Google Scholar]
  11. Dalby M. A. Effect of tetrabenazine on extrapyramidal movement disorders. Br Med J. 1969 May 17;2(5654):422–423. doi: 10.1136/bmj.2.5654.422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. EHRINGER H., HORNYKIEWICZ O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960 Dec 15;38:1236–1239. doi: 10.1007/BF01485901. [DOI] [PubMed] [Google Scholar]
  13. GREENFIELD J. G., BOSANQUET F. D. The brain-stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry. 1953 Nov;16(4):213–226. doi: 10.1136/jnnp.16.4.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Godwin-Austen R. B., Tomlinson E. B., Frears C. C., Kok H. W. Effects of L-dopa in Parkinson's disease. Lancet. 1969 Jul 26;2(7613):165–168. doi: 10.1016/s0140-6736(69)91417-2. [DOI] [PubMed] [Google Scholar]
  15. Gottfries C. G., Gottfries I., Roos B. E. Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism. J Neurochem. 1969 Sep;16(9):1341–1345. doi: 10.1111/j.1471-4159.1969.tb05984.x. [DOI] [PubMed] [Google Scholar]
  16. Guldberg H. C., Yates C. M. Some studies of the effects of chlorpromazine, reserpine and dihydroxyphenylalanine on the concentrations of homovanillic acid, 3,4-dihydroxyphenylacetic acid and 5-hydroxyindol-3-ylacetic acid in ventricular cerebrospinal fluid of the dog using the technique of serial sampling of the cerebrospinal fluid. Br J Pharmacol Chemother. 1968 Jul;33(3):457–471. doi: 10.1111/j.1476-5381.1968.tb00494.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966 Jun;18(2):925–964. [PubMed] [Google Scholar]
  18. Klawans H. C., Paulson G. W., Barbeau A. Predictive test for Huntington's chorea. Lancet. 1970 Dec 5;2(7684):1185–1186. doi: 10.1016/s0140-6736(70)90367-3. [DOI] [PubMed] [Google Scholar]
  19. Korf J., Valkenburgh-Sikkema T. Fluorimetric determination of 5-hydroxyindoleacetic acid in human urine and cerebrospinal fluid. Clin Chim Acta. 1969 Nov;26(2):301–306. doi: 10.1016/0009-8981(69)90383-0. [DOI] [PubMed] [Google Scholar]
  20. Pakkenberg H. The effect of tetrabenazine in some hyperkinetic syndromes. Acta Neurol Scand. 1968;44(3):391–393. doi: 10.1111/j.1600-0404.1968.tb05581.x. [DOI] [PubMed] [Google Scholar]
  21. Pullar I. A., Weddell J. M., Ahmed R., Gillingham F. J. Phenolic acid concentrations in the lumbar cerebrospinal fluid of Parkinsonian patients treated with L-dopa. J Neurol Neurosurg Psychiatry. 1970 Dec;33(6):851–857. doi: 10.1136/jnnp.33.6.851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rinne U. K., Sonninen V., Palo J. Excretion of homovanillic and vanilmandelic acid in patients with extrapyramidal disorders. Psychiatr Neurol (Basel) 1966;151(6):321–327. doi: 10.1159/000127310. [DOI] [PubMed] [Google Scholar]
  23. SOURKES T. L., PIVNICKI D., BROWN W. T., WISEMAN-DISTLER H., MURPHY G. F., SANKOFF I., SAINTCYR S. A CLINICAL AND METABOLIC STUDY OF DOPA (3, 4-DIHYDROXYPHENYLALANINE) AND METHYLDOPA IN HUNTINGTON'S CHOREA. Psychiatr Neurol (Basel) 1965;149:7–27. doi: 10.1159/000128799. [DOI] [PubMed] [Google Scholar]
  24. WILLIAMS C. M., MAURY S., KIBLER R. F. Normal excretion of homovanillic acid in the urine of patients with Huntington's chorea. J Neurochem. 1961 Feb;6:254–256. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES